Recombinant Human GHR protein (mFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

mFc Tag

Activity

not tested

Cat no : Eg3936

---

Validation Data Gallery

• 

  Purity of Recombinant Human GHR was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-Human GHR protein Ala27-Tyr264 (Accession# P10912-1) with a mosue IgG Fc tag at the C-terminus.
• GeneID: 2690
• Accession: P10912-1
• PredictedSize: 54.3 kDa
• SDS-PAGE: 60-80 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

GH is a peptide hormone with many pleiotropic actions, including the regulation of metabolism, postnatal growth, cognition, immune, cardiac and renal systems and gut function. GH exerts these actions primarily through alterations in gene expression, initiated by activation of its membrane receptor GHR and the resultant activation of the associated JAK2 and Src family kinases. GH receptor (GHR) is a member of the cytokine receptor family. Mutations in GHR gene have been associated with Laron syndrome, also known as the GH insensitivity syndrome (GHIS), a disorder characterized by short stature.

References:

1.	Panaro MA, Calvello R, et al. (2022) Methods Protoc. 5(4):53. 
2.	Erman A, Wabitsch M, et al. (2011) Int J Obes (Lond). 35(12):1520-9. 
3.	Glad CAM, Svensson PA, et al. (2019) J Clin Endocrinol Metab. 104(5):1459-1470. 
4.	Erman A, Veilleux A, et al. (2011) Int J Obes (Lond). 35(12):1511-9. 
5.	Stróżewska W, Durda-Masny M, et al. (2022) Genes (Basel). 13(5):856.